CLSDQ · Clearside Biomedical, Inc. · Executive Compensation
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. Based on our current plans and forecasted expenses and our cash and cash equivalents, we do not believe we will be able to fund our operations for the next 12 months from the date of this filing.”View the 10-Q filed Nov 14, 2025
Market Cap
$1.30M
Shares
5.23M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| George Lasezkay | President and Chief Executive Officer | $1,538,627 |
| Charles A. Deignan | Chief Financial Officer | $854,406 |
| Thomas Ciulla | Former Chief Medical Officer and Chief Development Officer | $363,500 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| George Lasezkay | President and Chief Executive Officer | $1,531,215 |
| Thomas Ciulla | Former Chief Medical Officer and Chief Development Officer | $936,284 |
| Charles A. Deignan | Chief Financial Officer | $876,029 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| George Lasezkay | President and Chief Executive Officer | $2,340,969 |
| Thomas Ciulla | Former Chief Medical Officer and Chief Development Officer | $1,825,420 |
| Charles A. Deignan | Chief Financial Officer | $1,544,816 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| George Lasezkay | President and Chief Executive Office r | $1,371,007 |
| Thomas Ciulla | Chief Medical Officer and Chief Development Officer | $671,663 |
| Charles A. Deignan | Chief Financial Officer | $641,590 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Daniel H. White | Former President and Chief Executive Officer | $1,381,713 |
| George Lasezkay | President and Chief Executive Officer | $1,045,192 |
| Brion Raymond | Former Chief Commercial Officer | $978,442 |
| Charles A. Deignan | Chief Financial Officer | $661,207 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Brion Raymond | Former Chief Commercial Officer | $954,296 |
| Daniel H. White | Former President and Chief Executive Officer | $675,122 |
| Charles A. Deignan | Chief Financial Officer | $434,361 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Anthony Gibney | member of the Board | Resigned | 2025-08-14 |
| Clay B. Thorp | Chairperson of the Board | Appointed | 2025-08-14 |
| Anthony Gibney | Chairperson | Resigned | 2025-08-14 |
| George Lasezkay | President and Chief Executive Officer | Terminated | 2025-07-17 |
| Anthony S. Gibney | director | Appointed | 2024-04-16 |